pulmonary%20arterial%20hypertension
PULMONARY ARTERIAL HYPERTENSION
Pulmonary arterial hypertension is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in increased pulmonary vascular resistance and ultimately leading to right heart failure.
It is a part of the spectrum of pulmonary hypertension, which is hemodynamic and pathophysiological condition defined as an increase in mean pulmonary arterial pressure ≥25 mmHg at rest.
Typical symptoms include progressive dyspnea on exertion, palpitations, fatigue, weakness, angina, syncope and abdominal distention.

Surgical Intervention

Balloon Atrial Septostomy (BAS)

  • Several experimental & clinical observations suggest that an atrial defect may be of benefit in the setting of pulmonary hypertension (PH) as it would allow right to left shunting which increases systemic output
    • This would increase systemic arterial oxygen saturation
    • It also decompresses the right atrium & ventricle therefore decreasing signs & symptoms of right heart failure
  • At present, indications for BAS are:
    • Patients who are in World Health Organization functional class (WHO FC) IV with severe syncope &/or right heart failure despite all available medical treatments
    • Palliative bridge to lung transplantation
    • Sole treatment modality when other options are not available
    • Considered in pulmonary arterial hypertension (PAH) associated with surgically corrected congenital hear disease (CHD), connective tissue disease, distal chronic thromboembolic pulmonary hypertension (CTEPH), pulmonary veno-occlusive disease & pulmonary capillary hemangiomatosis
    • May be considered before severe hemodynamic compromise & end-organ dysfunction occur
  • Should be performed only at institutions with significant procedural & clinical experience
  • Avoided in patients with a baseline mean right atrial pressure (RAP) of 20 mmHg & O2 saturation at rest of <85% on room air

Transplantation

  • There is no agreement on the optimal type of transplantation for patients with PAH, whether single lung, double lung or combined heart & lung
  • Indicated in PAH patients when they have an unacceptable response to PAH therapies seen in FC III or IV
  • Due to lack of effective medical therapeutic regimen, patients with pulmonary veno-occlusive disease & pulmonary capillary hemangiomatosis should be candidates for transplantation at diagnosis
  • Survival rates in PAH patients undergoing transplant: 66% at 1 year, 57% at 3 years, 47% at 5 years & 27% at 10 years
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
05 Aug 2015
The five A’s algorithm for quitting tobacco use is to ask, advise, assess, assist and arrange, while the five R’s stand for relevance, risks, rewards, roadblocks and repetition, says a specialist.
05 Jan 2018
At a recent dinner symposium at Shangri-La Kuala Lumpur, Dr Omar Usmani discussed the importance of inhaler devices in the management of asthma and chronic obstructive pulmonary disease (COPD).
27 Dec 2017
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.
Pearl Toh, 27 Dec 2017
The presence of eczema or atopic dermatitis with concurrent allergic sensitization at 1 year of age was associated with an increased risk of developing asthma and food allergy in later childhood at 3 years old, according to the CHILD* study.